Rozanolixizumab (Synonyms: UCB7665) |
Catalog No.GC66364
One-Click Copy Product Info
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1584645-37-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Rozanolixizumab is a high affinity humanized immunoglobulin G4 monoclonal anti-body directed against human neonatal Fc receptor (FcRn)[1]. Rozanolixizumab binds with high affinity (dissociation constant 0.023 and 0.034nM at pH 6.0 and pH 7.4)[2]. Rozanolixizumab for 1h treatment dose-dependently inhibits human FcRn-mediated recycling of human IgG in vitro with an IC50 of 0.41nM[2]. Rozanolixizumab is an agent approved for both anti-AChR and anti-MuSK antibody-positive gMG in USA[1].
Rozanolixizumab (0.0001-100μg/mL; 4h) reduced the surface labeling of the high-affinity FcγR and FcγRI in human monocyte-derived macrophages[3].
Rozanolixizumab (30mg/kg; i.v.) for a single administration reduced the plasma IgG concentrations in cynomolgus monkeys; Rozanolixizumab (10, 30, 100 or 250mg/kg; i.v.) for a single administration rapidly decreased the plasma IgG in muFcRn−/− huFcRn Tg32 transgenic mice[2]. Rozanolixizumab (150mg/kg; from gestation day 20 until delivery; q3d; s.q.) decreased the offspring’s IgG levels at birth from pregnant female cynomolgus monkeys[4].
References:
[1] Hoy S M. Rozanolixizumab: first approval [J]. Drugs, 2023, 83(14): 1341-1347.
[2] Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration [J]. MAbs, 2018, 10(7): 1111-1130.
[3] Qureshi O S, Sutton E J, Bithell R F, et al. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro [J]. MAbs, 2024, 16(1): 2300155.
[4] Cauvin A, Brady K, Cavagnaro J, et al. Evaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys [J]. Reprod Toxicol, 2025, 132: 108823.
| Cell experiment [1]: | |
|
Cell lines |
MDCK cells |
|
Preparation Method |
MDCK cells over-expressing human FcRn were plated in a 96-well plate and incubated overnight at 37℃, 5% CO2, to allow cells to adhere. The cells were incubated with Rozanolixizumab for 1h. IgG released into the supernatant was measured using a meso scale discovery (MSD) assay with an anti-human IgG capture antibody and a streptavidin-sulpho tag reveal antibody (MSD). |
|
Reaction Conditions |
0.41nM; 1h |
|
Applications |
Rozanolixizumab inhibited the recycling of human IgG by human FcRn-transfected MDCK cells. |
| Animal experiment [1]: | |
|
Animal models |
Male cynomolgus monkeys |
|
Preparation Method |
Adult male cynomolgus monkeys were administered with a 5, 10 or 30mg/kg dose on Day 0. Control animals received the same doses of vehicle (PBS). Blood samples were taken at regular intervals for analysis of total plasma IgG. |
|
Dosage form |
5, 10 and 30mg/kg; i.v. |
|
Applications |
Rozanolixizumab reduced the plasma IgG concentrations. |
References: [1] Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration [J]. MAbs, 2018, 10(7): 1111-1130. | |
| Cas No. | 1584645-37-3 | SDF | |
| Synonyms | UCB7665 | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)